Biotage Launches New 24 Well Pyrosequencing(R) System

Next Generation Pyrosequencing(R) System; PyroMark(TM)Q24 Pyrosequencing
Technology in a 24 Well Format for Low Throughput Epigenetic Studies

UPPSALA, Sweden, March 31 /PRNewswire/ -- Pyrosequencing AB, a subsidiary
of Biotage AB today announced the launch of PyroMark(TM)Q24 the latest in the
range of Pyrosequencing(R) Systems. This new high-performance platform
includes a complete software package for the study of genetic and epigenetic
variation of genes, providing CpG methylation allele quantification and
mutation analysis. These studies are used for a wide range of clinical
research, for example the identification and tracking of changes involved in
various forms of cancer. Studying these changes using Pyrosequencing(R)
technology, which is based on the principals of sequencing by synthesis, is
an ideal choice for genetic analysis in clinical research. The output
information is based on real sequence data providing integrated quality
control and security in the quality of the results.
The system, aimed at lower throughput needs, optimizes the management of
fewer samples. The 24 well plate format and the ability to run and analyze
both mutation and methylation assays on the same plate provides an ideal
solution for managing low sample numbers or mixed analysis needs while
providing the accuracy, flexibility and convenience offered by
Pyrosequencing(R) technology.
Until now Pyrosequencing(R) technology has only been available in higher
throughput systems, placing it out of the reach of many researchers. "With
the introduction of the new PyroMark(TM)Q24 system we plan to open up the
availability of Pyrosequencing(R) technology to many more researchers." Said
Torben Jorgensen President and CEO of Biotage AB.
The PyroMark(TM)Q24 performance has been successfully demonstrated at
sites in the US and Europe. Pyromark(TM)Q24 was shown to provide reproducible
and reliable results at the Dept of Pathology, Uppsala University Hospital
for clinical diagnostics in oncology.
According to Jakob Lindmark VP Sales and Marketing for Biosystems unit at
Biotage the PyroMark(TM)Q24 is the first in a series of solutions for
different applications in this lower throughput format.
About Biotage
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the areas of
genetic analysis and medicinal chemistry. In 2005 operations and products
were acquired from the American company Argonaut, further strengthening the
medicinal chemistry product range. The customers include the world's top 30
pharmaceutical companies, the world's top 20 biotech companies, and leading
academic institutes. The company is headquartered in Uppsala and has offices
in the U.S., Japan, UK, Germany and several other European countries. Biotage
has 336 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on
the OMX Nordic Exchange Stockholm AB. Website: http://www.biotage.com
Contact:
Jakob Lindmark
VP Sales and Marketing for Biosystems
Tel: +46-706-566022
Jakob.lindmark@eu.biotage.com

Biotage AB
Kungsgatan 76
SE-753 18 Uppsala
Tel: +46-18-56-59-00

SOURCE Biotage AB

Contact: Jakob Lindmark, VP Sales and Marketing for Biosystems, Tel:
+46-706-566022, Jakob.lindmark@eu.biotage.com; Biotage AB, Kungsgatan 76,
SE-753 18 Uppsala, Tel+46-18-56-59-00